Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

HuntingEagles Aug. 12 at 10:51 PM

$QNRX float?

0 · Reply

prismmarketview Aug. 12 at 1:45 PM

Nasdaq: $QNRX #QuoinPharmaceuticals latest #NETHERTONNOW episode features international advocate Mandy Aldwin-Easton, sharing the raw reality of living with Netherton Syndrome—a painful, life-limiting rare skin disorder. Her story underscores the urgent need for effective treatments as Quoin advances its lead therapy, QRX003, through pivotal trials. Watch her powerful message here: https://www.youtube.com/watchv=b2RXfrx8OvM&t=45s Full Article: https://prismmarketview.com/quoin-pharmaceuticals-spotlights-patient-advocate-in-latest-netherton-now-episode/

0 · Reply

JoseGilberto109 Aug. 8 at 11:12 PM

Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $BQ $EQ $QNRX $HSDT $GIBO pennies

0 · Reply

Tradingforfunz Aug. 8 at 5:55 PM

$QNRX need 20

0 · Reply

d_risk Aug. 8 at 2:56 PM

$QNRX - Quoin Pharmaceuticals, Ltd. - 10Q - Updated Risk Factors QNRX flags new and expanded risks: Nasdaq bid price non-compliance and potential delisting, a rising $62.7M deficit with just $7.8M in cash, and ongoing doubts about liquidity and ability to continue without new capital. #Pharmaceuticals #CapitalRaising #NasdaqCompliance #LiquidityConcerns #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/QNRX/10-Q/2025-08-07

0 · Reply

ZacksSCR Aug. 7 at 9:24 PM

$QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline https://buff.ly/eFvCcgm

0 · Reply

BullishSkull Aug. 7 at 7:46 PM

$QNRX monster rally

0 · Reply

prismmarketview Aug. 7 at 1:34 PM

$QNRX Reports Strong Q2 as QRX003 Advances in Rare Skin Disease Trials #QuoinPharmaceuticals continues to build momentum with meaningful progress across clinical, regulatory, and advocacy fronts. The company’s lead candidate, QRX003, is advancing in pivotal trials for Netherton Syndrome, with early data also supporting potential in other rare skin diseases. https://prismmarketview.com/quoin-reports-strong-q2-as-late-stage-netherton-syndrome-trial-progress-fuels-rare-dermatology-pipeline-expansion/

0 · Reply

StayPresent Aug. 2 at 1:18 AM

$QNRX on their way to another RS. This leadership group of idiots will get this company delisted hopefully. POS

0 · Reply

Schiellerup Jul. 31 at 2:01 PM

$QNRX

1 · Reply

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Jul 29, 2025, 8:30 AM EDT - 20 days ago

Quoin Pharmaceuticals Provides Product Portfolio Update

May 20, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 5 months ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 5 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 6 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 6 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 7 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 8 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 8 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 8 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 8 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Oct 31, 2024, 4:05 PM EDT - 10 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

HuntingEagles Aug. 12 at 10:51 PM

$QNRX float?

0 · Reply

prismmarketview Aug. 12 at 1:45 PM

0 · Reply

JoseGilberto109 Aug. 8 at 11:12 PM

0 · Reply

Tradingforfunz Aug. 8 at 5:55 PM

$QNRX need 20

0 · Reply

d_risk Aug. 8 at 2:56 PM

0 · Reply

ZacksSCR Aug. 7 at 9:24 PM

$QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline https://buff.ly/eFvCcgm

0 · Reply

BullishSkull Aug. 7 at 7:46 PM

$QNRX monster rally

0 · Reply

prismmarketview Aug. 7 at 1:34 PM

0 · Reply

StayPresent Aug. 2 at 1:18 AM

$QNRX on their way to another RS. This leadership group of idiots will get this company delisted hopefully. POS

0 · Reply

Schiellerup Jul. 31 at 2:01 PM

$QNRX

1 · Reply

JamesBenjaMin Jul. 31 at 1:00 AM

PRFX Hovering near its lows with a tiny float and deal news likely around the corner. This biotech has real IP, and once the deal closes, catalysts could stack fast data, partnerships, or regulatory movement. Low risk from here… high potential reward. $ACXP $QNRX $CYTO $ENSC

1 · Reply

CaliforniaRunners Jul. 29 at 9:03 PM

$QNRX going to 20

1 · Reply

CaliforniaRunners Jul. 29 at 8:33 PM

Looks like volume and momentum are going to be shifting back in to MTEX! Shorts overextended and now bulls can have them trapped at the bottom. MTEX Could pull a huge multi day run - only 600k float! Don't miss MTEX ... $ILLR $BTC.X $KITT $QNRX any news

0 · Reply

RobertVanhuss215 Jul. 29 at 3:04 PM

$QNRX works in neuropsychiatric R&D, but AITX is generating recurring revenue now — through robotics adoption across education and logistics, priced way below sector comps at 4× revenue.

0 · Reply

prismmarketview Jul. 29 at 2:24 PM

Pipeline Update from Quoin Pharmaceuticals (Nasdaq: $QNRX) @QuoinPharma is advancing QRX003 toward potential commercialization as the first approved treatment for Netherton Syndrome. Two pivotal clinical trials remain on track, with an NDA submission anticipated in the second half of 2026. The company has active studies across the U.S., Europe, and the Middle East. Positive early data supports expansion into Peeling Skin Syndrome, and the topical rapamycin program is advancing toward clinical trials in 2026. Quoin is entering pre-commercialization mode while continuing to grow its rare disease pipeline. https://prismmarketview.com/quoin-advances-qrx003-toward-commercialization-in-netherton-syndrome-and-expands-rare-disease-pipeline/

0 · Reply

Pipelinepivots Jul. 29 at 12:31 PM

PRFX deal could close anyway Tiny float. Huge mission. Targeting post surgery pain without addictive opioids and they’ve got the tech to back it. One positive trial or partnership, and this could explode. Biotech sleepers like this don’t stay quiet for long…. $ACXP $QNRX $DRUG

0 · Reply

SpacemanAlerts Jul. 28 at 9:17 PM

$QNRX

0 · Reply

Pipelinepivots Jul. 28 at 6:10 PM

PRFX deal closing any day! Opioid-free pain relief is the future and PRFX is ahead of the curve. FDA-backed tech, low float, and huge unmet demand. One trial update or partner deal and this goes vertical. Nobody’s watching… I am. $ACXP $ENSC $QNRX

0 · Reply

StayPresent Jul. 22 at 5:53 PM

$QNRX still a pos

0 · Reply

TwongStocks Jul. 17 at 8:11 PM

$QNRX They filed the definitive proxy for the shareholder meeting on Aug 21. https://www.sec.gov/ix?doc=/Archives/edgar/data/1671502/000110465925068650/tm252555-3_def14a.htm All proposals similar to the prelim proxy that was filed on July 7 👇. Big item is Prop 2, the request to increase the authorized share capital from 100m to 5B. Record date is close of business July 16. If you held shares at close on July 16, you are eligible to vote. At the record date, there were 20,585,830 ordinary shares outstanding, represented by 588,166 ADSs.

0 · Reply

TestacularTommy Jul. 17 at 12:06 AM

$QNRX worst 7k i ever spent, down 99%, my average is $6900🤣 what a joke,from all the R/S, thought monkey pox was going to keep this alive, what a scam, people use to defend this company, iremember the dsy it shot up like 1000% ,igot smoked, been a bagger since, shuld i just sell for $7K loss this year, or try to atleast get 1k back lol idnt think its possible

0 · Reply

TESLA557 Jul. 14 at 6:45 PM

$QNRX Nice uptrend, steady

0 · Reply

Market Cap	4.40M
Revenue (ttm)	0.00
Net Income (ttm)	-8.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,300
Avg Vol	6,198
Day's Range	N/A - N/A
Shares Out	588,000.00
Stochastic %K	66%
Beta	1.44
Analysts	Strong Sell
Price Target	$40.67